Compare Amylx Pharmaceuticals Inc (AMLX) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Intuitive Surgical, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.8 (market cap $2.64B), while Intuitive Surgical, Inc. trades at $402.87 (market cap $141.75B). The key difference: Intuitive Surgical, Inc. is far larger — about 53.7× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| AMLX | ISRG | |
|---|---|---|
Market Cap | $2.64B | $141.75B |
Sector | Health | Health |
52-Week High | $24.19 | $592.85 |
52-Week Low | $7.82 | $332.02 |
Enterprise Value | $2.39B | $136.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Intuitive Surgical (ISRG) trades at $393.38, up 3.85% on the day, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The stock exhibits premium valuation metrics, including a P/E of 46.01 and P/S of 13.08, supported by robust revenue growth, which reached $10.06B in 2025, and high net income margins of 28.45%. Recent news highlights analyst upgrades and optimism around the da Vinci 5 system's adoption.
The outlook remains positive given durable demand and innovation, but risks include heightened competition and valuation sensitivity. Wall Street consensus is bullish with a $518.10 price target, implying significant upside, though investors should weigh premium multiples against growth sustainability and competitive pressures in the medtech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
